Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.62
(-8.47%)
SEK 1.62
(-8.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -126.07 Million SEK | -14.14% |
| 2022 | -110.45 Million SEK | -83.79% |
| 2021 | -60.1 Million SEK | -49.58% |
| 2020 | -40.18 Million SEK | -34.76% |
| 2019 | -29.81 Million SEK | -37.29% |
| 2018 | -21.71 Million SEK | -20.95% |
| 2017 | -17.95 Million SEK | -21.01% |
| 2016 | -14.83 Million SEK | -222.66% |
| 2015 | -4.59 Million SEK | 29.22% |
| 2014 | -6.49 Million SEK | -41.77% |
| 2013 | -4.58 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -23.56 Million SEK | 43.19% |
| 2023 FY | -126.07 Million SEK | -14.14% |
| 2023 Q3 | -27.84 Million SEK | -10.0% |
| 2023 Q1 | -32.19 Million SEK | 13.48% |
| 2023 Q2 | -25.31 Million SEK | 21.36% |
| 2023 Q4 | -41.47 Million SEK | -48.94% |
| 2022 Q2 | -23.31 Million SEK | -12.82% |
| 2022 FY | -110.45 Million SEK | -83.79% |
| 2022 Q4 | -37.2 Million SEK | -27.09% |
| 2022 Q3 | -29.27 Million SEK | -25.6% |
| 2022 Q1 | -20.66 Million SEK | -8.0% |
| 2021 Q2 | -14.31 Million SEK | -16.96% |
| 2021 FY | -60.1 Million SEK | -49.58% |
| 2021 Q1 | -12.23 Million SEK | -0.57% |
| 2021 Q4 | -19.13 Million SEK | -32.7% |
| 2021 Q3 | -14.41 Million SEK | -0.72% |
| 2020 FY | -40.18 Million SEK | -34.76% |
| 2020 Q2 | -8.28 Million SEK | 4.39% |
| 2020 Q3 | -11.06 Million SEK | -33.52% |
| 2020 Q4 | -12.16 Million SEK | -10.01% |
| 2020 Q1 | -8.66 Million SEK | 15.84% |
| 2019 Q2 | -5.99 Million SEK | 2.55% |
| 2019 Q3 | -7.43 Million SEK | -24.09% |
| 2019 Q1 | -6.14 Million SEK | -0.05% |
| 2019 FY | -29.81 Million SEK | -37.29% |
| 2019 Q4 | -10.29 Million SEK | -38.52% |
| 2018 Q1 | -3.95 Million SEK | -7.21% |
| 2018 FY | -21.71 Million SEK | -20.95% |
| 2018 Q4 | -6.14 Million SEK | -6.3% |
| 2018 Q3 | -5.78 Million SEK | -3.05% |
| 2018 Q2 | -5.6 Million SEK | -41.78% |
| 2017 Q2 | -4.65 Million SEK | -33.03% |
| 2017 Q1 | -3.49 Million SEK | 40.88% |
| 2017 FY | -17.95 Million SEK | -21.01% |
| 2017 Q4 | -3.69 Million SEK | 39.68% |
| 2017 Q3 | -6.11 Million SEK | -31.49% |
| 2016 Q3 | -4.05 Million SEK | -48.46% |
| 2016 FY | -14.83 Million SEK | -222.66% |
| 2016 Q4 | -5.91 Million SEK | -46.05% |
| 2016 Q2 | -2.72 Million SEK | -27.12% |
| 2016 Q1 | -2.14 Million SEK | 0.14% |
| 2015 Q4 | -2.14 Million SEK | 0.0% |
| 2015 Q2 | -618 Thousand SEK | 0.0% |
| 2015 Q1 | -618 Thousand SEK | 0.0% |
| 2015 FY | -4.59 Million SEK | 29.22% |
| 2015 Q3 | -2.14 Million SEK | -247.73% |
| 2014 FY | -6.49 Million SEK | -41.77% |
| 2013 FY | -4.58 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 49.365% |
| Ziccum AB (publ) | -21.56 Million SEK | -484.754% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -668.691% |
| BioArctic AB (publ) | 252.64 Million SEK | 149.902% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -14819.882% |
| Mendus AB (publ) | -100.65 Million SEK | -25.259% |
| Genovis AB (publ.) | 54.22 Million SEK | 332.504% |
| Intervacc AB (publ) | -93.57 Million SEK | -34.724% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -712.745% |
| Active Biotech AB (publ) | -46.48 Million SEK | -171.218% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 800.056% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -127.499% |
| Aptahem AB (publ) | -10.1 Million SEK | -1147.66% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 60.787% |
| Kancera AB (publ) | -65.04 Million SEK | -93.833% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 6.347% |
| Fluicell AB (publ) | -26.87 Million SEK | -369.039% |
| Saniona AB (publ) | -81.06 Million SEK | -55.521% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -919.101% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -196.607% |
| AcouSort AB (publ) | -17.48 Million SEK | -620.953% |
| Xintela AB (publ) | -57.23 Million SEK | -120.261% |
| Abliva AB (publ) | -96.54 Million SEK | -30.581% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 61.184% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -3496.947% |
| OncoZenge AB (publ) | -15.9 Million SEK | -692.812% |
| Amniotics AB (publ) | -29.07 Million SEK | -333.643% |
| 2cureX AB (publ) | -36.36 Million SEK | -246.707% |
| CombiGene AB (publ) | -36.3 Million SEK | -247.259% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -761.154% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 67.202% |
| Camurus AB (publ) | 532.35 Million SEK | 123.682% |
| Corline Biomedical AB | -1.78 Million SEK | -6951.063% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 30.256% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -202.457% |
| I-Tech AB | 24.43 Million SEK | 615.953% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 84.011% |
| Cyxone AB (publ) | -21.66 Million SEK | -482.028% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -18.976% |
| Biosergen AB | -27.26 Million SEK | -362.399% |
| Cantargia AB (publ) | -290.01 Million SEK | 56.529% |
| NextCell Pharma AB | -43.17 Million SEK | -192.024% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 30.256% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -637.43% |
| Nanologica AB (publ) | -69.96 Million SEK | -80.2% |
| SynAct Pharma AB | -224.49 Million SEK | 43.842% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -185.388% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -426.307% |
| LIDDS AB (publ) | -40.67 Million SEK | -209.96% |
| Lipum AB (publ) | -37.25 Million SEK | -238.415% |
| BioInvent International AB (publ) | -369.94 Million SEK | 65.921% |
| Alzinova AB (publ) | -16.52 Million SEK | -663.061% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 50.257% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1871.971% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -9.559% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -526.014% |
| Simris Alg AB (publ) | -36.63 Million SEK | -244.133% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 13.983% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 59.387% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -13.667% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -990.031% |